Everolimus: side effect profile and management of toxicities in breast cancer.
about
Everolimus plus exemestane for the treatment of advanced breast cancer: a review of subanalyses from BOLERO-2A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy.The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers.Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions.Everolimus-Based Therapy versus Chemotherapy among Patients with HR+/HER2- Metastatic Breast Cancer: Comparative Effectiveness from a Chart Review Study.mTORC1 directly phosphorylates and activates ERα upon estrogen stimulation.Safety, Efficacy, and Patient Acceptability of Everolimus in the Treatment of Breast Cancer.Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer.Incidence and risk of rash to mTOR inhibitors in cancer patients--a meta-analysis of randomized controlled trials.Targeting the mammalian target of rapamycin pathway with everolimus: implications for the management of metastatic breast cancer.Cardiovascular prevention in the cancer survivor.mTOR inhibitor-induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm.Hyaluronic Acid Nanohydrogel Loaded With Quercetin Alone or in Combination to a Macrolide Derivative of Rapamycin RAD001 (Everolimus) as a New Treatment for Hormone-Responsive Human Breast Cancer.Safety of mTOR inhibitors in breast cancer.Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors.The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress.mTORC1/2 inhibition preserves ovarian function and fertility during genotoxic chemotherapy.Everolimus-based therapy in patients with hormone receptor-positive, HER2(-) advanced breast cancer: management considerations.Longitudinal serum metabolomics evaluation of trastuzumab and everolimus combination as pre-operative treatment for HER-2 positive breast cancer patients.Hyaluronic Acid-Decorated Chitosan Nanoparticles for CD44-Targeted Delivery of Everolimus
P2860
Q28085004-3309E504-83DC-40E4-A59B-B20F9D7CEA1AQ33410791-AD39AA5C-86DA-4CF9-B922-AC2358448753Q33937368-54F2FB89-8B25-4B11-BC0C-28D80A69A2F1Q34657786-7E68E83A-4F93-4BCC-BA3A-9A23C292CF88Q35675851-941A974D-59B1-4A14-9E6A-C04B600DEDFEQ36858723-90DC0864-582B-4A84-8E60-A8AB7B2FEDD7Q37559332-A868DCCC-ABB0-4A1A-B797-3362C8476A08Q38199328-89C04052-9FC7-4E76-BB48-9597B2091BA4Q38219039-A1983C01-45EC-4537-8865-FFEA5033D860Q38223222-D75CAF79-C1B2-40C5-8761-0A10B2D8E07EQ38338228-3D08894C-4283-490D-9CB7-E0AB13556356Q38603164-51D8C9BE-42AC-4659-8A72-1225BBEC22F6Q38747583-6BC7A7D3-88C8-4CF2-AF92-C9A303959BFDQ38841039-AAB10C4E-85A0-4482-AEA1-10AA3AA0566CQ38948950-E0948CAA-893E-47EA-8181-E36CD14FCF47Q39312902-72931D5B-9D2C-47A4-B457-BD4F004D3A31Q41710033-424436E2-BB7F-4951-BE48-2F8CD33F6E82Q44680921-E5348518-4005-47A6-B9AD-4B32865D0B42Q47119839-438BF8EC-8D47-4A3B-B881-A3C8DCA8A435Q58796793-1A291D07-8B72-45E9-93D5-B9A0E3950ED9
P2860
Everolimus: side effect profile and management of toxicities in breast cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Everolimus: side effect profile and management of toxicities in breast cancer.
@en
type
label
Everolimus: side effect profile and management of toxicities in breast cancer.
@en
prefLabel
Everolimus: side effect profile and management of toxicities in breast cancer.
@en
P2093
P2860
P1476
Everolimus: side effect profile and management of toxicities in breast cancer.
@en
P2093
Amelia Zelnak
Elisavet Paplomata
Ruth O'Regan
P2860
P2888
P304
P356
10.1007/S10549-013-2630-Y
P407
P577
2013-08-02T00:00:00Z
P6179
1048475036